Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer

By Hoff Paulo   Saad Everardo   Pazdur Richard   Wolff Robert   Lassere Yvonne   Bogaard Karla   Abbruzzese James  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 307-313

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum

By Royce Melanie E.   Rowinsky Eric K.   Hoff Paulo M.   Coyle John   DeJager Robert   Pazdur Richard   Saltz Leonard B.  

Investigational New Drugs, Vol. 22, Iss. 1, 2004-01 ,pp. : 53-61

Springer Publishing Company

Access to resources Recommend Favorite

The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium

By Nimeiri Halla   Singh Deepti   Kasza Kristen   Taber David   Ansari Rafat   Vokes Everett   Kindler Hedy  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 854-858

Springer Publishing Company

Access to resources Recommend Favorite

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

By Gelmon K.   Hirte H.   Fisher B.   Walsh W.   Ptaszynski M.   Hamilton M.   Onetto N.   Eisenhauer E.  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 263-275

Springer Publishing Company

Access to resources Recommend Favorite

Ixabepilone stacks up in metastatic breast cancer

By  

Inpharma, Vol. 1, Iss. 1595, 2007-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite